SAN DIEGO, July 16, 2025--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to ...
Revelation Biosciences (REVB) announced safety and activity data for its Phase 1b PRIME clinical study in stage 3 and 4 chronic kidney disease patients. The primary endpoint to evaluate the safety and ...
SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Revelation Biosciences ( (REVB)) has ...
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, today announced it has successfully reached a ...
PARIS, France—(UPDATED) A small, randomized trial may breathe new life into the concept of using a drug-coated balloon (DCB) instead of a stent in acute MI, particularly in younger patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback